MovDisordV3, PascalFrancis, Corpus, bibRecord, 001298

Excessive Dopamine Neuron Loss in Progressive Supranuclear Palsy

Identifieur interne : 001298 ( PascalFrancis/Corpus ); précédent : 001297; suivant : 001299

Excessive Dopamine Neuron Loss in Progressive Supranuclear Palsy

Auteurs : Karen E. Murphy ; Tanya Karaconji ; Craig D. Hardman ; Glenda M. Halliday

Source :

Movement disorders [ 0885-3185 ] ; 2008.

RBID : Pascal:08-0199373

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Dopamine, Mort cellulaire, Mésencéphale, Neurone.

English descriptors

KwdEn :
- Cell death, Dopamine, Midbrain, Nervous system diseases, Neuron, Parkinson disease.

Abstract

Progressive supranuclear palsy (PSP) and Parkinson's disease (PD) differ in their response to dopaminergic replacement therapies, despite having a similar degree of neuronal degeneration in the dopaminergic substantia nigra. We observed more widespread dopamine neuron loss in the extranigral A10 midbrain cell groups in PSP compared with PD. These cell groups innervate subcortical and cortical regions and may be required for adequate response to levodopa therapy.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 23`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Excessive Dopamine Neuron Loss in Progressive Supranuclear Palsy`
A11	`01`	`1`		`@1 MURPHY (Karen E.)`
A11	`02`	`1`		`@1 KARACONJI (Tanya)`
A11	`03`	`1`		`@1 HARDMAN (Craig D.)`
A11	`04`	`1`		`@1 HALLIDAY (Glenda M.)`
A14	`01`			`@1 Prince of Wales Medical Research Institute @2 Randwick @3 AUS @Z 1 aut. @Z 4 aut.`
A14	`02`			`@1 Department of Anatomy, School of Medical Sciences, University of New South Wales @2 Sydney @3 AUS @Z 2 aut. @Z 3 aut.`
A20				`@1 607-610`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000183361080200`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 8 ref.`
A47	`01`	`1`		`@0 08-0199373`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	`@0 Progressive supranuclear palsy (PSP) and Parkinson's disease (PD) differ in their response to dopaminergic replacement therapies, despite having a similar degree of neuronal degeneration in the dopaminergic substantia nigra. We observed more widespread dopamine neuron loss in the extranigral A10 midbrain cell groups in PSP compared with PD. These cell groups innervate subcortical and cortical regions and may be required for adequate response to levodopa therapy.`
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 09`
C03	`03`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 09`
C03	`03`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 09`
C03	`04`	`X`	`FRE`	`@0 Mort cellulaire @5 10`
C03	`04`	`X`	`ENG`	`@0 Cell death @5 10`
C03	`04`	`X`	`SPA`	`@0 Muerte celular @5 10`
C03	`05`	`X`	`FRE`	`@0 Mésencéphale @5 11`
C03	`05`	`X`	`ENG`	`@0 Midbrain @5 11`
C03	`05`	`X`	`SPA`	`@0 Mesencéfalo @5 11`
C03	`06`	`X`	`FRE`	`@0 Neurone @5 12`
C03	`06`	`X`	`ENG`	`@0 Neuron @5 12`
C03	`06`	`X`	`SPA`	`@0 Neurona @5 12`
C07	`01`	`X`	`FRE`	`@0 Catécholamine @5 37`
C07	`01`	`X`	`ENG`	`@0 Catecholamine @5 37`
C07	`01`	`X`	`SPA`	`@0 Catecolamina @5 37`
C07	`02`	`X`	`FRE`	`@0 Neurotransmetteur @5 38`
C07	`02`	`X`	`ENG`	`@0 Neurotransmitter @5 38`
C07	`02`	`X`	`SPA`	`@0 Neurotransmisor @5 38`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central @5 39`
C07	`03`	`X`	`ENG`	`@0 Central nervous system @5 39`
C07	`03`	`X`	`SPA`	`@0 Sistema nervioso central @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 40`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 40`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 41`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 41`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 41`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 42`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 42`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 42`
C07	`07`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 43`
C07	`07`	`X`	`ENG`	`@0 Central nervous system disease @5 43`
C07	`07`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 43`
N21				`@1 126`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0199373 INIST
ET :	Excessive Dopamine Neuron Loss in Progressive Supranuclear Palsy
AU :	MURPHY (Karen E.); KARACONJI (Tanya); HARDMAN (Craig D.); HALLIDAY (Glenda M.)
AF :	Prince of Wales Medical Research Institute/Randwick/Australie (1 aut., 4 aut.); Department of Anatomy, School of Medical Sciences, University of New South Wales/Sydney/Australie (2 aut., 3 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 4; Pp. 607-610; Bibl. 8 ref.
LA :	Anglais
EA :	Progressive supranuclear palsy (PSP) and Parkinson's disease (PD) differ in their response to dopaminergic replacement therapies, despite having a similar degree of neuronal degeneration in the dopaminergic substantia nigra. We observed more widespread dopamine neuron loss in the extranigral A10 midbrain cell groups in PSP compared with PD. These cell groups innervate subcortical and cortical regions and may be required for adequate response to levodopa therapy.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Dopamine; Mort cellulaire; Mésencéphale; Neurone
FG :	Catécholamine; Neurotransmetteur; Système nerveux central; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Dopamine; Cell death; Midbrain; Neuron
EG :	Catecholamine; Neurotransmitter; Central nervous system; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Dopamina; Muerte celular; Mesencéfalo; Neurona
LO :	INIST-20953.354000183361080200
ID :	08-0199373

Links to Exploration step

Pascal:08-0199373

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Excessive Dopamine Neuron Loss in Progressive Supranuclear Palsy</title>
<author><name sortKey="Murphy, Karen E" sort="Murphy, Karen E" uniqKey="Murphy K" first="Karen E." last="Murphy">Karen E. Murphy</name>
<affiliation><inist:fA14 i1="01"><s1>Prince of Wales Medical Research Institute</s1>
<s2>Randwick</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Karaconji, Tanya" sort="Karaconji, Tanya" uniqKey="Karaconji T" first="Tanya" last="Karaconji">Tanya Karaconji</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Anatomy, School of Medical Sciences, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hardman, Craig D" sort="Hardman, Craig D" uniqKey="Hardman C" first="Craig D." last="Hardman">Craig D. Hardman</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Anatomy, School of Medical Sciences, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M." last="Halliday">Glenda M. Halliday</name>
<affiliation><inist:fA14 i1="01"><s1>Prince of Wales Medical Research Institute</s1>
<s2>Randwick</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0199373</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0199373 INIST</idno>
<idno type="RBID">Pascal:08-0199373</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001298</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Excessive Dopamine Neuron Loss in Progressive Supranuclear Palsy</title>
<author><name sortKey="Murphy, Karen E" sort="Murphy, Karen E" uniqKey="Murphy K" first="Karen E." last="Murphy">Karen E. Murphy</name>
<affiliation><inist:fA14 i1="01"><s1>Prince of Wales Medical Research Institute</s1>
<s2>Randwick</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Karaconji, Tanya" sort="Karaconji, Tanya" uniqKey="Karaconji T" first="Tanya" last="Karaconji">Tanya Karaconji</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Anatomy, School of Medical Sciences, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hardman, Craig D" sort="Hardman, Craig D" uniqKey="Hardman C" first="Craig D." last="Hardman">Craig D. Hardman</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Anatomy, School of Medical Sciences, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M." last="Halliday">Glenda M. Halliday</name>
<affiliation><inist:fA14 i1="01"><s1>Prince of Wales Medical Research Institute</s1>
<s2>Randwick</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cell death</term>
<term>Dopamine</term>
<term>Midbrain</term>
<term>Nervous system diseases</term>
<term>Neuron</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Dopamine</term>
<term>Mort cellulaire</term>
<term>Mésencéphale</term>
<term>Neurone</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Progressive supranuclear palsy (PSP) and Parkinson's disease (PD) differ in their response to dopaminergic replacement therapies, despite having a similar degree of neuronal degeneration in the dopaminergic substantia nigra. We observed more widespread dopamine neuron loss in the extranigral A10 midbrain cell groups in PSP compared with PD. These cell groups innervate subcortical and cortical regions and may be required for adequate response to levodopa therapy.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Excessive Dopamine Neuron Loss in Progressive Supranuclear Palsy</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MURPHY (Karen E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KARACONJI (Tanya)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HARDMAN (Craig D.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HALLIDAY (Glenda M.)</s1>
</fA11>
<fA14 i1="01"><s1>Prince of Wales Medical Research Institute</s1>
<s2>Randwick</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Anatomy, School of Medical Sciences, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>607-610</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000183361080200</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>8 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0199373</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Progressive supranuclear palsy (PSP) and Parkinson's disease (PD) differ in their response to dopaminergic replacement therapies, despite having a similar degree of neuronal degeneration in the dopaminergic substantia nigra. We observed more widespread dopamine neuron loss in the extranigral A10 midbrain cell groups in PSP compared with PD. These cell groups innervate subcortical and cortical regions and may be required for adequate response to levodopa therapy.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Mort cellulaire</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Cell death</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Muerte celular</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Mésencéphale</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Midbrain</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Mesencéfalo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Neurone</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Neuron</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Neurona</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fN21><s1>126</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0199373 INIST</NO>
<ET>Excessive Dopamine Neuron Loss in Progressive Supranuclear Palsy</ET>
<AU>MURPHY (Karen E.); KARACONJI (Tanya); HARDMAN (Craig D.); HALLIDAY (Glenda M.)</AU>
<AF>Prince of Wales Medical Research Institute/Randwick/Australie (1 aut., 4 aut.); Department of Anatomy, School of Medical Sciences, University of New South Wales/Sydney/Australie (2 aut., 3 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 4; Pp. 607-610; Bibl. 8 ref.</SO>
<LA>Anglais</LA>
<EA>Progressive supranuclear palsy (PSP) and Parkinson's disease (PD) differ in their response to dopaminergic replacement therapies, despite having a similar degree of neuronal degeneration in the dopaminergic substantia nigra. We observed more widespread dopamine neuron loss in the extranigral A10 midbrain cell groups in PSP compared with PD. These cell groups innervate subcortical and cortical regions and may be required for adequate response to levodopa therapy.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Dopamine; Mort cellulaire; Mésencéphale; Neurone</FD>
<FG>Catécholamine; Neurotransmetteur; Système nerveux central; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Dopamine; Cell death; Midbrain; Neuron</ED>
<EG>Catecholamine; Neurotransmitter; Central nervous system; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Dopamina; Muerte celular; Mesencéfalo; Neurona</SD>
<LO>INIST-20953.354000183361080200</LO>
<ID>08-0199373</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001298 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001298 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0199373
   |texte=   Excessive Dopamine Neuron Loss in Progressive Supranuclear Palsy
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Excessive Dopamine Neuron Loss in Progressive Supranuclear Palsy

Excessive Dopamine Neuron Loss in Progressive Supranuclear Palsy

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri